Report overview
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
This report aims to provide a comprehensive presentation of the global market for Oncology Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biosimilars. This report contains market size and forecasts of Oncology Biosimilars in global, including the following market information:
Global Oncology Biosimilars Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Oncology Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monoclonal Antibody Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oncology Biosimilars include Celltrion, Biocon, Dr. Reddy?s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oncology Biosimilars companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oncology Biosimilars Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Oncology Biosimilars Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Global Oncology Biosimilars Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Oncology Biosimilars Market Segment Percentages, by Application, 2022 (%)
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Global Oncology Biosimilars Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Oncology Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oncology Biosimilars revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Oncology Biosimilars revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celltrion
Biocon
Dr. Reddy?s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oncology Biosimilars, market overview.
Chapter 2: Global Oncology Biosimilars market size in revenue.
Chapter 3: Detailed analysis of Oncology Biosimilars company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oncology Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
